Values as of: 2024-10-30
COMMON STOCK | Biotechnology |
Last Closing
USD 2.34Change
-0.02 (-0.85)%Market Cap
USD 0.79BVolume
3.22MAnalyst Target
N/AVerdict
Verdict
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.
Company Website : https://www.nuvationbio.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| BHVN | Biohaven Pharmaceutical Holdin.. |
-0.49 (-0.96%) |
USD 5.14B |
| RCUS | Arcus Biosciences Inc |
-0.41 (-2.50%) |
USD 1.58B |
| DNA | Ginkgo Bioworks Holdings |
-0.17 (-2.12%) |
USD 0.50B |
| ANRO | Alto Neuroscience, Inc. |
+0.02 (+0.50%) |
USD 0.37B |
| ADCT | ADC Therapeutics SA |
-0.06 (-1.99%) |
USD 0.29B |
| CYBN | Cybin Inc |
-0.59 (-5.62%) |
USD 0.23B |
| ANVS | Annovis Bio Inc |
-0.20 (-2.05%) |
USD 0.13B |
| ARMP | Armata Pharmaceuticals Inc |
-0.01 (-0.27%) |
USD 0.08B |
| PLX | Protalix Biotherapeutics Inc |
N/A |
USD 0.08B |
| OSTX | OS Therapies Incorporated |
+0.06 (+2.18%) |
USD 0.07B |
N/A
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 54.97% | 53% | F | 90% | A- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 54.97% | 53% | F | 90% | A- | ||
| Trailing 12 Months | |||||||
| Capital Gain | 101.72% | 56% | F | 91% | A- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 101.72% | 56% | F | 91% | A- | ||
| Trailing 5 Years | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -16.45% | 15% | F | 3% | F | ||
| Dividend Return | -16.45% | 15% | F | 3% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 52.86% | 65% | D | 18% | F | ||
| Risk Adjusted Return | -31.13% | 18% | F | 9% | A- | ||
| Market Capitalization | 0.79B | 93% | A | 54% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total free cash flow in the most recent four quarters.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers median on a price to book value basis.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company had negative total cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
